brightlight schreef op 4 maart 2020 17:37:
[...]
Sales in Japan have begun, that is for sure (on a RUO basis). It was in one of their press releases and I checked with investor relations to be sure. Unfortunately Japan has been hit hard by Corona, so I am not sure if this will have an impact on their roll-out or not.
This year I am mainly looking out for U.S. approvals. Unfortunately Bcart's slide on that subject is not very specific. Are they still preparing FDA registration or have the requests been submitted? More news tomorrow?
In my opinion Bcart will and should grow their earnings faster: in the 35% to 45% range. I think that is feasible and necessary unless they manage to get their margins up.
BL